Suppr超能文献

黄酮类化合物作为 P-糖蛋白介导的多药耐药的逆转剂:体外评估,重点是抗癫痫药物。

Flavonoid compounds as reversing agents of the P-glycoprotein-mediated multidrug resistance: An in vitro evaluation with focus on antiepileptic drugs.

机构信息

CICS-UBI - Health Sciences Research Centre, University of Beira Interior, Av. Infante D. Henrique, 6200-506 Covilhã, Portugal; CNC - Center for Neuroscience and Cell Biology, University of Coimbra, 3004-517 Coimbra, Portugal.

CICS-UBI - Health Sciences Research Centre, University of Beira Interior, Av. Infante D. Henrique, 6200-506 Covilhã, Portugal; UDI-IPG, Research Unit for Inland Development, Polytechnic Institute of Guarda, 6300-749 Guarda, Portugal.

出版信息

Food Res Int. 2018 Jan;103:110-120. doi: 10.1016/j.foodres.2017.10.010. Epub 2017 Oct 12.

Abstract

The pharmacoresistance to antiepileptic drugs (AEDs) remains a major unsolved therapeutic need. The overexpression of multidrug transporters, as the P-glycoprotein (P-gp), at the level of the blood-brain barrier of epileptic patients has been suggested as a key mechanism underlying the refractory epilepsy. Thus, efforts have been made to search for therapeutically useful P-gp inhibitors. Herein, the strategy of flavonoid/AED combined therapy was exploited as a possible approach to overcome the P-gp-mediated pharmacoresistance. For this purpose, several in vitro studies were performed using Madin-Darby canine kidney II (MDCK II) cells and those transfected with the human multidrug resistance-1 (MDR1) gene, overexpressing the P-gp (MDCK-MDR1). Overall, the results showed that baicalein, (-)-epigallocatechin gallate, kaempferol, quercetin and silymarin, at 200μM, produced a marked increase on the intracellular accumulation of rhodamine 123 in MDCK-MDR1 cells, potentially through inhibiting the P-gp activity. In addition, with the exception of lamotrigine, all other AEDs tested (phenytoin, carbamazepine and oxcarbazepine) and their active metabolites (carbamazepine-10,11-epoxide and licarbazepine) demonstrated to be P-gp substrates. Furthermore, the most promising flavonoids as P-gp inhibitors promoted a significant increase on the intracellular accumulation of the AEDs (excluding lamotrigine) and their active metabolites in MDCK-MDR1 cells, evidencing to be important drug candidates to reverse the AED-resistance. Thus, the co-administration of AEDs with baicalein, (-)-epigallocatechin gallate, kaempferol, quercetin and silymarin should continue to be explored as adjuvant therapy for refractory epilepsy. List of chemical compounds studied in this article: Baicalein (PubChem CID: 5,281,605); Carbamazepine (PubChem CID: 2554); Carbamazepine 10,11-epoxide (PubChem CID: 2555); (-)-Epigallocatechin gallate (PubChem CID: 65064); Kaempferol (PubChem CID: 5280863); Lamotrigine (PubChem CID: 3878); Licarbazepine (PubChem CID: 114709); Oxcarbazepine (PubChem CID: 34312); Phenytoin (PubChem CID: 1775); Silymarin (PubChem CID: 7073228); Quercetin (PubChem CID: 5280343); Verapamil (PubChem CID: 2520).

摘要

抗癫痫药物(AED)的耐药性仍然是一个未解决的主要治疗需求。在癫痫患者的血脑屏障水平,多药转运蛋白(如 P-糖蛋白(P-gp))的过度表达被认为是难治性癫痫的关键机制之一。因此,人们一直在努力寻找治疗上有用的 P-gp 抑制剂。在此,本文利用黄酮类/AED 联合治疗策略作为克服 P-gp 介导的耐药性的可能方法。为此,使用 Madin-Darby 犬肾 II(MDCK II)细胞和转染人多药耐药基因 1(MDR1)的细胞(过表达 P-gp(MDCK-MDR1))进行了几项体外研究。总的来说,结果表明,黄芩素、(-)-表没食子儿茶素没食子酸酯、山奈酚、槲皮素和水飞蓟素在 200μM 时,可显著增加 MDCK-MDR1 细胞中罗丹明 123 的细胞内积累,可能是通过抑制 P-gp 活性。此外,除拉莫三嗪外,测试的所有其他 AED(苯妥英、卡马西平和奥卡西平)及其活性代谢物(卡马西平-10,11-环氧和利卡西平)均被证明是 P-gp 底物。此外,作为 P-gp 抑制剂最有前途的黄酮类化合物可显著增加 MDCK-MDR1 细胞中 AED(不包括拉莫三嗪)及其活性代谢物的细胞内积累,表明它们是逆转 AED 耐药性的重要候选药物。因此,应继续探索将 AED 与黄芩素、(-)-表没食子儿茶素没食子酸酯、山奈酚、槲皮素和水飞蓟素联合给药作为难治性癫痫的辅助治疗。本文研究的化合物列表:黄芩素(PubChem CID:5,281,605);卡马西平(PubChem CID:2554);卡马西平 10,11-环氧(PubChem CID:2555);(-)-表没食子儿茶素没食子酸酯(PubChem CID:65064);山奈酚(PubChem CID:5280863);拉莫三嗪(PubChem CID:3878);利卡西平(PubChem CID:114709);奥卡西平(PubChem CID:34312);苯妥英(PubChem CID:1775);水飞蓟素(PubChem CID:7073228);槲皮素(PubChem CID:5280343);维拉帕米(PubChem CID:2520)。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验